Cequa (Cyclosporine Ophthalmic Solution) for Dry Eye: Mechanism and Clinical Use
Cequa (cyclosporine 0.09% ophthalmic solution) is a calcineurin inhibitor approved to increase tear production in dry eye disease (DED). It uses nanomicellar technology (NCELL®) for enhanced corneal penetration—addressing cyclosporine's historical bioavailability challenge.
Mechanism of Action
- T-cell inhibition: Cyclosporine binds cyclophilin, inhibiting calcineurin phosphatase, blocking NFAT nuclear translocation, and decreasing IL-2, IFN-γ, and other T-cell cytokines.
- Reduces ocular surface inflammation: DED is T-cell mediated (CD4+ Th1/Th17 infiltration). Cyclosporine interrupts this inflammatory cycle.
- Restores lacrimal gland function: Reduced inflammation leads to increased aqueous tear production.
- Improves tear quality: Increases mucin (MUC5AC) production by goblet cells, improving tear film stability and ocular surface protection.
- NCELL® nanomicelles: ~22 nm particles enhance corneal permeation 3-fold vs. emulsion (Restasis®), allowing lower concentration (0.09% vs. 0.05%) with better delivery.
Clinical Efficacy (Phase 3: OTTER-1 and OTTER-2)
- Primary endpoint (Month 3): ≥10 mm increase in Schirmer score (with anesthesia): Cequa ~15–17% vs. vehicle ~7–8%.
- Signs: Improvement in corneal fluorescein staining.
- Symptoms: Reduction in Ocular Surface Disease Index (OSDI) and eye dryness scores.
- Onset: Some improvement by 1 month; maximal effect by 3–6 months.
Dosing and Administration
- One drop (0.09%) in each eye twice daily (~12 hours apart).
- Single-use vials (preservative-free). Use immediately; discard after use.
- Wait ≥15 minutes before administering other eye drops.
- Can be used with artificial tears (separate by 15 minutes).
Safety and Tolerability
- Common (1–5%): Instillation site pain (burning/stinging), conjunctival hyperemia, blepharitis, headache, upper respiratory infection.
- No systemic immunosuppression: Negligible blood levels.
- No increased infection risk in clinical trials.
- Contact lenses: Remove before instillation; reinsert 15 minutes after.
Comparison: Cequa vs. Restasis vs. Xiidra vs. Tyrvaya
| Cequa | Restasis | Xiidra | Tyrvaya | |
|---|---|---|---|---|
| Active | CsA 0.09% | CsA 0.05% | Lifitegrast 5% | Varenicline 0.03 mg |
| Mechanism | Calcineurin inhib. | Calcineurin inhib. | LFA-1 antagonist | Cholinergic agonist |
| Vehicle | Nanomicellar | Emulsion | Solution | Nasal spray |
| Dosing | BID | BID | BID | BID nasal |
| Onset | 1–3 mo | 3–6 mo | 2–12 wk | Days–weeks |
| Burning | ~20% | ~17% | ~15% | Sneezing ~80% |
Clinical Pearls
- Set expectations: 3–6 months for full effect. Don't stop early.
- Refrigeration not required (room temperature OK).
- Cost/access: Check formulary, manufacturer savings card, patient assistance programs.
- Combine with: preservative-free artificial tears, lid hygiene, omega-3 supplementation, environmental modification.
- If inadequate at 6 months: reassess diagnosis (MGD, neuropathic, autoimmune), consider add-on or switch.
Cequa offers improved cyclosporine delivery for dry eye disease. Patience and consistency are key—this treats the disease, not just symptoms.
Eye & Vision Disorders - Related Articles
- Understanding Progressive Lenses: A Comprehensive Guide
- Effective Solutions for Puffy Eyes: Causes & Treatments
- Finding Your Perfect Frames: A Face Shape Guide to Glasses
- Thin & Lightweight Eyeglass Lenses: Options & Technology
- Eye Bleeding from a Cut: Immediate Medical Attention Required
- Pink Eye (Conjunctivitis): Affected Areas and Potential Complications
- Ramadan Fasting & Eye Drops: Do They Break the Fast?
